Worldwide Access to Treatment for End-Stage Kidney Disease: A Systematic Review

Liyanage, Thaminda; Ninomiya, T.; Jha, Vivekanand

doi:10.1016/j.jvs.2015.08.003

Cited by 51 publications

(66 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 It is noteworthy that T2D remains a primary factor in accounting for the substantial increase in ESKD worldwide. 11 The Global Burden of Disease study has shown that, in the last two decades, a remarkable component of the observed increase in the rates of age-standardized death and disability-adjusted life years attributable to CKD relates to the ascending role of DKD. 12 Thus, HF and DKD remain major health burdens in patients with T2D.…”

Section: Heart Failure and Kidney Disease: The Neglected Side Of Prmentioning

confidence: 99%

Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti‐hyperglycaemic drug matters?

Giugliano

Ceriello

Nicola

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

We are observing a resurgence of major diabetic vascular complications after a period of dramatic decrease during the period 1990 to 2010. The classical division of cardiovascular prevention into primary (with an event) and secondary (without an event) is largely used to describe cardiovascular risk in type 2 diabetes (T2D); however, there is evidence that the cardiovascular risk in diabetes may range from highest in patients who experienced a previous cardiovascular event to mild in patients with the main risk factors at target. Herein, we present details of the 14 cardiovascular outcome trials (CVOTs) published to date, including the total population investigated, and their separation into primary (T2D + multiple risk factors) and secondary prevention (T2D + established cardiovascular disease [CVD]) populations as detailed within the trials. We also summarize evidence for the effects of dipeptidyl peptidase‐4 inhibitors (DPP‐4i), glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) and sodium glucose co‐transporter‐2 inhibitors (SGLT‐2i) versus placebo on the risk of major cardiovascular events (MACE), heart failure (HF) and diabetic kidney disease (DKD). In primary prevention, SGLT‐2i reduce both the risk of hospitalization for HF and progression of DKD; in secondary prevention, SGLT‐2i are effective on the three endpoints, DPP‐4i are neutral, while GLP1‐RA show mixed results.

show abstract

Section: Heart Failure and Kidney Disease: The Neglected Side Of Prmentioning

confidence: 99%

Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti‐hyperglycaemic drug matters?

Giugliano

Ceriello

Nicola

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…There have been repeated calls to increase ACP from governments, medical associations and patient and consumer groups. [1][2][3][4] In addition to providing patient-centred care that respects choice, ACP can benefit families and healthcare professionals. 5…”

Section: Supporting Informationmentioning

confidence: 99%

“…Dialysis-dependent chronic kidney disease (CKD5D) is associated with significant morbidity and mortality, and prevalence is increasing both within Australia and internationally at unprecedented rates. [1][2][3][4][5][6] In 2016 there were 12 706 patients requiring maintenance haemodialysis in Australia, an increase of approximately 30% over the preceding decade. 5 In no other jurisdiction is this increase as conspicuous as in the Northern Territory (NT).…”

Section: Introductionmentioning

confidence: 99%

Resource use and outcomes in patients with dialysis‐dependent chronic kidney disease admitted to intensive care

Secombe

Chiang

Pawar

2019

Internal Medicine Journal

View full text Add to dashboard Cite

Background Central Australia (CA) has a high prevalence of haemodialysis‐dependent chronic kidney disease (CKD5D). CKD5D is associated with an increased need for critical care services. Aims To describe the demographic features, critical care resource use and outcomes of patients with CKD5D requiring intensive care admission in CA. Methods Retrospective matched cohort database study. Patients with CKD5D who required admission for critical illness between 1 July 2015 and 30 June 2016 were identified using the Centre for Outcome and Resource Evaluation Outcome Measurement and Evaluation Tool (CORE COMET) and matched with patients without CKD5D. The primary outcome was all cause mortality. Secondary outcomes explored use of critical care and other ongoing healthcare use. Results There were 621 critical care admissions during the study period. Of these, CKD5D patients comprised 88 admissions (14%), representing 63 patients. Compared to matched controls, these patients had a similar mortality at a median follow up of 463 days (17% vs 22%, P = 0.50) which did not change when patients with an intensive care unit length of stay (ICU LoS) less than 4 days were excluded. CKD5D patients had a shorter median ICU LoS (1.3 vs 2.9). Although those with CKD5D had higher healthcare resource use, the rate of utilisation remained unchanged by their ICU admission. Conclusions This retrospective observational matched cohort study examining the burden of disease amongst CKD5D patients in CA suggests that there is no additional mortality burden in this group, nor do they require significantly higher critical care resources compared to a matched cohort.

show abstract

“…Most of this increase will be in developing countries of Asia and Africa. 35 Access to RRT in the emerging world is dependent mostly on the health care expenditures and economic strength of individual countries, with the relationship between income and access to RRT being almost linear in low-and middleincome countries. 19,36 In Latin America, RRT prevalence and kidney transplantation rates correlate significantly with gross national income and health expenditure, 37 whereas in India and Pakistan, less than 10% of all ESRD patients have access to RRT.…”

Section: Disparities In Access To Renal Replacement Therapymentioning

confidence: 99%

Chronic Kidney Disease in Disadvantaged Populations

Garcia-Garcia

Jha

2015

Transplantation

View full text Add to dashboard Cite

The increased burden of CKD in disadavantaged populations is due to both global factors and population-specific issues. Low socioeconomic status and poor access to care contribute to health care disparities, and exacerbate the negative effects of genetic or biologic predisposition. Provision of appropriate renal care to these populations requires a two-pronged approach: expanding the reach of dialysis through development of low-cost alternatives that can be practiced in remote locations, and implementation and evaluation of cost-effective prevention strategies. Kidney transplantation should be promoted by expanding deceased donor transplant programs and use of inexpensive, generic immunosuppressive drugs. The message of WKD 2015 is that a concerted attack against the diseases that lead to ESRD, by increasing community outreach, better education, improved economic opportunity, and access to preventive medicine for those at highest risk, could end the unacceptable relationship between CKD and disadvantage in these communities.

show abstract

Worldwide Access to Treatment for End-Stage Kidney Disease: A Systematic Review

Cited by 51 publications

References 23 publications

Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti‐hyperglycaemic drug matters?

Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti‐hyperglycaemic drug matters?

Resource use and outcomes in patients with dialysis‐dependent chronic kidney disease admitted to intensive care

Chronic Kidney Disease in Disadvantaged Populations

Contact Info

Product

Resources

About